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Objective: Preclinical and clinical studies support a role for brain-derived neurotrophic factor (BDNF) in
the pathophysiology of stress-related mood disorders. Furthermore, BDNF seems to be linked to anti-
depressant action. Available pharmacological treatments for depression are characterized by signiﬁcant
limitations with low efﬁcacy and a major delay until treatment response. This demonstrates the urgent
need for more efﬁcient and fast-acting antidepressants. Besides ketamine, sleep deprivation (SD) as well
as partial sleep deprivation (PSD) are effective and fast-acting antidepressant methods. However, the
underlying molecular mechanisms of SD are not well understood; especially possible mechanisms
explaining the rapid, but transient antidepressant effect of SD are unknown.
Methods: We evaluated serum BDNF from 28 patients suffering from major depressive disorder (MDD),
who were naïve to SD therapy at seven different time points within a 32 h time window before (day 0)
and after PSD (day 1). PSD-response was assessed by 6-Items of the Hamilton Depression Rating Scale
(HDRS) before (day 0) and at follow-up after 2 weeks (FU2).
Results: PSD induced a very fast increase in BDNF serum levels at day 1 which parallels clinical ﬁndings,
since levels increased with decreasing depression scores in all participants. Notably, responders showed
a signiﬁcant diurnal BDNF serum variation not only after PSD but already before PSD treatment, while
diurnal proﬁle of serum BDNF from non-responders did not vary.
Conclusions: The elasticity in diurnal serum BDNF variation is associated with favourable treatment
response to PSD in patients suffering from MDD. Therefore, a normalized BDNF serum proﬁle which
oscillates in a circadian fashion seems to precede, rather than follow a favourable treatment outcome in
depressed patients. Furthermore the fast increase of BDNF is comparable to effects seen with ketamine
infusion.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
There is growing evidence that both the pathophysiology and
the treatment of major depressive disorder (MDD) are linked to
alterations of neurotrophic factor expression such as brain-derived
neurotrophic factor (BDNF) in various brain regions, including thefor Brain Aging and Mental
olecular Neuroscience, Uni-
Basel, Wilhelm Klein-Strasse
x: þ41 61 325 5577.
.
Ltd. This is an open access article uhippocampus (Duman and Monteggia, 2006). These can involve
reversible changes, which explain the link between depressive
episodes and subsequent recovery with neuronal plasticity. Expo-
sure to stress, which is related with, but not required for the onset
of MDD (Kendler et al., 1999) in humans, advances or worsens
depressive episodes (Gold and Chrousos, 2002). Preclinical and
clinical studies demonstrate that reductions of the total volume of
neurons and neuronal loss occur in stress and depression in the
adult hippocampus (Warner-Schmidt and Duman, 2006). These
hippocampal alterations can be reversed by chronic antidepressant
treatment (Warner-Schmidt and Duman, 2006).
Under chronic stress conditions the hypothalamicepituitarye
adrenal (HPA) axis regulation may become deregulated. Such HPAnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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zation after successful treatment are major ﬁndings in patients with
MDD(Holsboer-Trachsler andSeifritz, 2000;Holsboer-Trachsleret al.,
1991; Holsboer and Barden, 1996).
BDNF has received much attention among candidate down-
stream effectors involved in antidepressant-mediated hippocampal
neurogenesis. Indeed, chronic treatment with different classes of
classic antidepressants (e.g. SSRIs and NSRIs) seems to be associ-
ated with increased BDNF expression in the hippocampus and
neurogenesis (Duman and Monteggia, 2006); likewise, a direct
infusion of BDNF into the hippocampus was sufﬁcient to produce
an antidepressant-like action in mouse models of depression
(Berman et al., 2000; Shirayama et al., 2002). Taken together,
multiple neurobiological mechanisms seem to be involved in
mediating the therapeutic effects of antidepressant therapy. Some
of these mechanisms seem to play a role for neuroprotection and
neurogenesis. The complexity could explain the slow onset of ac-
tion in antidepressant treatments (Duman, 2004). Furthermore,
most currently available antidepressants primarily target the
noradrenergic and serotonergic systems.
Recent evidence implicates a glutamatergic dysregulation
(Berman et al., 2000; Zarate et al., 2006) introducing the N-methyl-
D-aspartate (NMDA) receptor antagonist, ketamine, which reveals
rapid antidepressant efﬁcacy at low doses (Berman et al., 2000). In
particular, patients with treatment-resistant depression beneﬁt
from sub-anaesthetic doses of ketamine with quick and persistent
antidepressant effects (Murrough et al., 2013; Zarate et al., 2006). It
is suggested, that the NMDA receptor blockade leads to an up-
regulation of the a-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor expression and subse-
quent activation of the intracellular mammalian target of rapamy-
cin (mTOR) cascade involved in ketamine's antidepressant action
(Li et al., 2010). This, in turn, is followed by an increase of syn-
aptogenesis, which might be mirrored by the neuroplasticity
marker BDNF (Autry et al., 2011; Duman and Li, 2012).
BDNF and its neurotrophic functions are connected particularly
to neuronal survival, memory, learning, appetite and sleep (Duman
et al., 2000; Faraguna et al., 2008), leading to the neurotrophin
hypothesis which claims that stress-related mood disorders result
from stress-induced decreases in BDNF expression (Duman et al.,
1997). Successful antidepressant treatment is able to reverse this
deﬁcit and is mediated by an increase in BDNF levels (Duman et al.,
1997). Cellular and molecular mechanisms underlying a rapid an-
tidepressant effect, like those shown for ketamine, seem to be
complex and indicate that neuronal plasticity is involved (Duman
and Li, 2012). Furthermore, Haile et al. demonstrated a rapid in-
crease of plasma BDNF levels 240 min after intravenous infusion
(Haile et al., 2014).
Circulating BDNF is found in both human serum and plasma and
a large amount is stored in human platelets (Fujimura et al., 2002).
However, the source of peripheral BDNF is not yet clear. Since the
protein can cross the blood brain-barrier in both directions,
circulating BDNF is correspondingly associated with cortical BDNF
concentrations (Karege et al., 2002) proposing peripheral BDNF as
a promising candidate biomarker in the association with depres-
sion and antidepressant treatment response. Several studies
showed that serum BDNF levels in drug-free MDD patients were
signiﬁcantly lower compared to healthy subjects (Shimizu et al.,
2003). Other studies reported that plasma BDNF levels were
lower in drug-free MDD patients (Karege et al., 2005; Lee et al.,
2007). Some clinical studies have evaluated the changes of
plasma or serum BDNF levels before and after antidepressant
treatments among MDD patients and most studies report increases
of BDNF levels after antidepressant treatment (Brunoni et al., 2011;
Piccinni et al., 2008), although very recent data indicate that theincrease in serum levels of BDNF during antidepressant treatment
appears to be conﬁned to some but not all antidepressants
(Molendijk et al., 2011). Nevertheless, different antidepressant
strategies including antidepressant drugs and electroconvulsive
therapy (ECT) were associated with an increase of BDNF levels
(Conti et al., 2007). Moreover, some studies provide important
evidence that an antidepressant-induced increase in BDNF levels is
more prominent in responders than non-responders (Lee and Kim,
2008) or even exclusively restricted to responders (Lee and Kim,
2008). Despite current ﬁndings of increased blood BDNF levels in
long-term treatment interventions, the underlying mechanism of
this systemic neurotrophic increase is not clariﬁed. It could be a
matter of downstream signalling initiated by distinct classes of
antidepressants like SSRIs and NSRIs, independent of neurogenesis,
or related to an adaptation device, which involves neuronal plas-
ticity and neurogenesis, altering synaptic transmission.
Sleep deprivation (SD) is a clinically well-documented, robust,
and fast-acting method for the treatment of severely depressed
patients (Giedke and Schwarzler, 2002). Other than SD the whole
night, partial sleep deprivation (PSD) in the second half of the
night has also shown comparable antidepressant effects in patients
with major depression (Giedke and Schwarzler, 2002). However,
the underlying molecular and cellular mechanisms of SD are not
well understood, especially those explaining the rapid, although
transient, antidepressant effect of SD, since a relapse into depres-
sion occurs in most patients following the recovery night (Beck
et al., 2010). Recent evidence indicates that an up-regulation of
BDNF gene expression after SD in rats might be relevant for its
mode of action (Conti et al., 2007; Hairston et al., 2004). Moreover,
evidence also supports a role for BDNF in the modulation and
mediation of circadian rhythms which seem to be disturbed in
mood disorders. Interestingly, the presence of a diurnal BDNF
rhythm was also recently demonstrated in healthy humans where
plasma BDNF displayed highest concentrations in the morning,
followed by a substantial decrease throughout the day, and the
lowest values at midnight (Begliuomini et al., 2008). However,
diurnal variation of blood BDNF was neglected until now in studies
investigating MDD patients.
In the present study, we wanted to explore the effect of partial
sleep deprivation (PSD) as an alternative antidepressant inter-
vention on serum BDNF levels. Therefore, we investigated the
acute effect of PSD on serum BDNF levels within a time window of
12 h during the day after PSD night in MDD patients. Furthermore,
due to the fact that BNDF levels oscillate in the periphery in a
circadian fashion, we monitored daily variations in serum BDNF
levels. In addition, we investigated whether baseline BDNF levels
before PSD and treatment-associated changes are related to
clinical and depressive symptoms and/or treatment response.
Thus, this study was speciﬁcally designed to obtain, for the ﬁrst
time, results on potential fast-acting effects of PSD on BDNF and,
concurrently, on daily peripheral BDNF proﬁles in MDD patients
to explore the hypothesis if a diurnal BDNF pattern might be
associated with prediction of antidepressant therapy response at
a very early stage of intervention. This is in contrast to all other
published studies where treatment related BDNF changes were
collected and analyzed no earlier than one to six weeks of anti-
depressive therapy.
2. Material and methods
2.1. Subjects and study design
Twenty-eight in- and out-patients (13 men, 15 women, age
45.1 ± 12.1 years; range 19e65 years) with the diagnosis of major
depression (DSM-IV and ICD-10) and according to the SCID
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published (Beck et al., 2010). Study design details, inclusion and
exclusion criteria were previously described in details by Beck
et al. (2010). The investigation was carried out in accordance
with the latest version of the Declaration of Helsinki and the
study protocol was approved by the local ethics committee. All
patients gave written informed consent after complete descrip-
tion of the study. Inclusion criteria comprised an HDRS-score of
15 and the presence of signiﬁcant daytime sleepiness and
severity of depression was evaluated by the 21-Item version of
Hamilton Depression Rating Scale (HDRS) (Hamilton, 1967). In
brief, all participants were naïve to sleep deprivation therapy and
randomly assigned to either additional modaﬁnil or placebo
treatment, to test the effect of modaﬁnil (200 mg/d) on micro-
sleep during PSD (Beck et al., 2010). According to ethical consid-
erations, all patients were treated with a monotherapy of 30 mg
mirtazapine daily at 9 pm throughout the study, which started
already 1 week before PSD intervention to ensure an adequate
stabilization period in all patients. PSD-response was assessed by
6-items of the HDRS covering the items depressive mood, feelings
of guilt, working and leisure activities, depressive inhibition,
psychological symptoms of anxiety, and somatic symptoms (Bech
et al., 1975). This subscale has been applied to assess changes of
depression in particular during PSD since sleep-related items e
present in the 21-items version e which could lead to a biased
response, are excluded. An improvement of at least 30% from
baseline was required to determine a PSD response. The modaﬁnil
group consisted of eight men and six women, age 46.2 ± 12.2
years (n ¼ 14, HDRS 21-items before PSD 21.71 ± 6.56 and at day
after PSD 15.71 ± 9.12; 6-items before PSD 9.43 ± 2.79 and at day
after PSD 6.50 ± 3.69) and the placebo group of ﬁve men and nine
women, age 43.9 ± 12.2 years (n ¼ 14, HDRS 21-items before PSD
21.79 ± 4.72 and at day after PSD 12.64 ± 8.38; 6-items before PSD
8.71 ± 2.40 and at day after PSD 5.07 ± 3.85; values of all ratings
were not different compared to modaﬁnil) (Beck et al., 2010).
Compared to placebo, modaﬁnil was efﬁcient in reducing daytime
microsleep following partial sleep deprivation but did not
enhance the antidepressive effects of PSD and did not stabilize
antidepressive effects over two weeks (Beck et al., 2010).
2.2. Serum sampling
For serum sampling blood was obtained in a serum separator
tube from the antecubital vein at seven different time points. Day
0 (before PSD) at 8 am (t1), 2 pm (t2) and 8 pm (t3) for baseline and
day 1 at 1.30 am (t4) during PSD, 8 am (t5), 2 pm (t6) and 8 pm (t7)
after PSD (Fig. 1). After 30 min of clotting time, whole blood wasFig. 1. Study design and serum sampling. Blood was drawn at day 0 (baseline) before PSD at 8
1 after PSD. Placebo controlled morning treatment with the stimulant modaﬁnil started duri
Hamilton Depression Rating Scale (HDRS) at days 0, 1 as well as after 2 weeks (day 14, FU2)centrifuged at 1000  g for 30 min to separate the serum. Serum
was collected in aliquots to avoid several freezing cycles and kept
at 80 C before assaying.
2.3. Measurement of serum BDNF levels
Serum BDNF levels were assessed with an enzyme-linked
immunoabsorbant assay (ELISA) kit (Promega BDNF Emax®, Mad-
ison, Wis., United States). Samples were appropriately diluted
(between 1:100 and 1:150) and detection of total soluble BDNF was
carried out in an antibody sandwich format as described in the
manufacturer's protocol. The absorbance was measured within
30 min in a microplate reader set at 450 nm, and a correction
wavelength set to 690 nm, to determine BDNF concentrations ac-
cording to the standard curve. All assays were carried out in
duplicate and means were calculated.
2.4. Questionnaires to assess potential confounders
Besides a sociodemographic questionnaire to assess sex, age and
BMI, participants had to indicate substance consumption, which
could interfere with biological analyses.
2.5. Statistical analysis
Analysis of variance (Two-way ANOVA) was used for multiple
group parametric comparisons with posthoc Bonferroni-corrected
t-tests. Associations between variables were computed with Pear-
son's correlations. To compare the effect size Cohen's d was calcu-
lated to compare serum BDNF values among subjects, responders
and non-responders. The level of signiﬁcance was set at p  0.05.
Preliminary calculations revealed that BDNF serum levels were
not associated with sex and age (rs < 0.20, p > 0.35) and smoking
(all ts < 1.56, p > 0.13). As a result, sex, age and smoking were not
entered as co-variates.
3. Results
3.1. Daily serum BDNF proﬁle from MDD patients before and after
PSD
Pre-PSD at baseline (day 0), a daily variation pattern could be
detected in serum BDNF levels from all participants (n ¼ 28) which
decreased during the day starting with the highest concentration in
the morning until BDNF concentrations reached their lowest level
after midnight (Fig. 2A). Post-PSD, serum BDNF levels of day 1 were
increased to 10.4% (at 8 am), 16.2% (at 2 pm) and 20.7% (at 8 pm)am (t1), 2 pm (t2), 8 pm (t3) and at 1:30 am (t4), 8 am (t5), 2 pm (t6) and 8 pm (t7) day
ng PSD and was maintained over 14 days. PSD-response was assessed by 6-items of the
of on-going treatment.
Fig. 2. Daily variation of serum BDNF levels. (A) Baseline serum BDNF levels (means ± SEM) decreased during the day starting with the highest concentration in the morning (8 am,
t1) until they reached the lowest level after midnight (1:30 am, t4) in all patients. (B) After PSD serum BDNF levels (means ± SEM) were elevated throughout day 1, relative to levels
at baseline (day 0) of 10.4% at 8 am, 16.2% at 2 pm and 20.7% at 8 pm. This difference in BDNF levels between baseline and day 1 was statistically signiﬁcant (F(1) ¼ 4.46; p ¼ 0.037).
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(Two-way ANOVA: treatment effect F(1)¼ 4.46; p¼ 0.037) (Fig. 2B).3.2. No effect of additional treatment with modaﬁnil on BDNF levels
To evaluate the effect of additional modaﬁnil treatment starting
at 1.30 am during PSD we compared serum BDNF levels of day 1
between patients with modaﬁnil and placebo treatment. A series of
Chi-square tests revealed no statistically signiﬁcant associations
between treatment condition and response (response day 1: c2(1,
n ¼ 25) ¼ 0.24, p ¼ 0.62; response day 2: c2(1, n ¼ 25) ¼ 0.05,
p¼ 0.82; response FU1 c2(1, n¼ 25)¼ 0.27, p¼ 0.87; response FU2:
c2(1, n ¼ 24) ¼ 1.34, p ¼ 0.27).3.3. Post-PSD BDNF and therapy response after 14 days
In a further step, we explored to what extent post-PSD serum
BDNF levels of day 1 exhibited similar diurnal pattern character-
istics for patients identiﬁed as long-term responders (35,7%, n¼ 10)
and non-responders (64.3%, n ¼ 18) (long-term HDRS-6 ratings
after twoweeks [FU2]; (Beck et al., 2010)) (Fig. 3A, B). PSD-response
was assessed by a subscale of 6-items of the HDRS to assess changes
of depression in particular during PSD, since sleep-related items,
which are designedly excluded in this subscale, could lead to a
biased response. Again, we recognized a prominent daily change of
post-PSD serum BDNF levels, but only for long-term responders.
Thus, FU2 responders showed signiﬁcantly higher serum BDNFFig. 3. Post-PSD serum BDNF levels. (A) After PSD (day 1) elevated serum BDNF levels (me
(means ± SEM) were associated with long-term response after 14 days, a diurnal pattern wa
variation did not exist for non-responders, since serum BDNF levels remained almost ﬂat
Correlation between post-PSD serum BDNF levels and depression severity improvement. Imp
14. Analyses showed a positive correlation of BDNF levels with improvement of depressionlevels post-PSD on day 1 at 8 am (t5) (t¼ 2.994, p¼ 0.007) and 2 pm
(t6) (t ¼ 2.851, p ¼ 0.010) compared to non-responders (Fig. 3B)
leading to a signiﬁcant group effect (F(1) ¼ 10.56; p ¼ 0.002).
Furthermore, effect size calculations emphasized higher BDNF
levels in FU2-responders at 8 am (t5) (d ¼ 1.54) and 2 pm (t6)
(d ¼ 1.37) on day 1, relative to non-responders. Importantly, there
was no observable diurnal baseline BDNF pattern for patients
speciﬁed as non-responders after 2 weeks (Fig. 3B). However, a
trend toward a slight diurnal change was recognizable (Fig. 3B),
which was clearly less pronounced compared to responders. In
agreement with other ﬁndings using different antidepressive
treatment approaches (Dell'Osso et al., 2010; Okamoto et al., 2008)
we could show a signiﬁcant correlation of HDRS-6 improvement
with increased post-PSD serum BDNF levels at 8 am (t5) in all pa-
tients after 2 weeks (rp ¼ 0.612; p ¼ 0.0025) (Fig. 3C).3.4. Pre-PSD BDNF and therapy response after 14 days
To explore if a diurnal variation could precede PSD we investi-
gated in an additional step whether serum BDNF levels at baseline
(day 0) exhibited diurnal pattern characteristics for patients iden-
tiﬁed as long-term responders (35,7%, n ¼ 10) and non-responders
(64,3%, n ¼ 18) (Beck et al., 2010) (Fig. 4A, B). PSD-response was
assessed by a subscale of 6-items of the HDRS to evaluate changes of
depressionparticularly during PSD, since sleep-related items,which
are excluded in this subscale, could lead to a biased response. Again,
BDNF levels at baseline were higher in long-term responders,ans ± SEM) vary modestly throughout the day. (B) When post-PSD serum BDNF levels
s most prominent in subjects who were identiﬁed as responders. This peculiar diurnal
throughout the day. **p  0.01 vs. corresponding BDNF levels in non-responders. (C)
rovement as percent change for Hamilton depression subscale (HDRS-6) ratings at day
severity across the sample (rp ¼ 0.612; p ¼ 0.002).
Fig. 4. Pre-PSD serum BDNF levels. (A) At baseline (day 0), before PSD intervention, serum BDNF levels (means ± SEM) vary throughout the day in a decreasing fashion. (B) When
pre-PSD serum BDNF levels were associated with long-term response after 14 days, a diurnal pattern was most prominent in subjects who were identiﬁed as responders compared
to non-responders. For non-responders serum BDNF levels (means ± SEM) remained ﬂat throughout the day. *p  0.05 vs. corresponding BDNF levels in non-responders. (C)
Correlation between pre-PSD serum BDNF levels and depression severity improvement. Improvement as percent change in Hamilton depression subscale (HDRS-6) ratings at day
14. Analyses showed a positive correlation of BDNF levels with improvement of depression severity across the sample (rp ¼ 0.516; p ¼ 0.001).
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group effect F(1) ¼ 5.85; p ¼ 0.0179), compared to non-responders.
Effect size calculations emphasized higher BDNF levels in FU2-
responders at 8 am (t1) (d ¼ 0.91) and 2 pm (t2) (d ¼ 0.71) at pre-
PSD baseline, relative to non-responders (Fig. 4B). Furthermore,
we could identify a prominent daily change of pre-PSD serum BDNF
levels in long-term responders. Once again, there was no diurnal
BDNF pattern observable for patients identiﬁed as non-responders
after 2 weeks (Fig. 4B). This ﬁnding was emphasized by a signiﬁ-
cant correlation of elevated pre-PSD serum levels at 8 am (t1) with
HDRS-6 improvement in all patients after 2 weeks (Fig. 4C)
(rp ¼ 0.516; p ¼ 0.001).
4. Discussion
Keyﬁndings of the present study indicate that BDNF serum levels
exhibited a signiﬁcant diurnal variation. This diurnal pattern was
especially prominent among responders when compared to non-
responders in a sample of patients suffering from MDD. Subjects
identiﬁed as responders after 2 weeks of follow-up (FU2) subse-
quent to PSD were associated with a daily change of serum BDNF
post-PSD at day 1 and even pre-PSD at baseline (day 0). This varia-
tion of peripheral BDNF concentration revealed characteristics of a
diurnal pattern since levels decreased during the day starting with
the highest concentration in the morning, whereas non-responders
did not exhibit diurnal serum BDNF variation. In consequence, we
conclude that the presence of a diurnal serum BDNF proﬁle in MDD
patients is powerfully linked with therapy response.
Of note, there is limited data available on diurnal variation of
blood BDNF levels in healthy subjects, but nothing is known from
MDD patients in this regard.
Most biological functions are expressed in an oscillating manner
within a 24-h circadian period, regulated by endogenous biological
clocks. A growing body of evidence also supports a role for BDNF
and its tropomyosine-related kinase receptor B (TrkB) in the
modulation and mediation of circadian rhythms. High levels of
BDNF and TrkB expression were demonstrated in the rat supra-
chiasmatic nucleus (SCN) and hippocampus (Katoh-Semba et al.,
2008). It was reported that BDNF protein and mRNA levels in the
rat SCN showed clear signs of variation over the course of a circa-
dian cycle. The SCN content of BDNF protein remained low
throughout the subjective day, began to rise early in the subjective
night, and reached peak levels near the middle of the subjective
night (Liang et al., 1998). Diurnal variation in BDNF protein
expression levels was demonstrated in the cerebellum, hippo-
campus, and cerebral cortex (Katoh-Semba et al., 2008). Moreover,recognition that circadian rhythm disruption also plays a key role in
mood disorders has led to the development of the new antide-
pressant agomelatine. Recent data from various groups showed
that agomelatine led to an increase in BDNF expression in treated
animals, and that this effect follows a speciﬁc temporal proﬁle
(Soumier et al., 2009). Interestingly, the presence of a diurnal BDNF
rhythm was also recently demonstrated in healthy humans (only
males were included in the study), where plasma BDNF displayed
highest concentrations in the morning (8 am), followed by a sub-
stantial decrease throughout the day, with lowest values at
midnight (Begliuomini et al., 2008). A similar circadian ﬂuctuation
in plasma BDNF levels was also found in women (Pluchino et al.,
2009), even if the amplitude of the variation in BDNF levels
appeared to be inﬂuenced by ovarian function with a blunted
diurnal rhythm in the luteal phase.
In the present study, we could conﬁrm parallel changes in
diurnal variation of serum BDNF in patients identiﬁed as re-
sponders of both gender. Therefore, together all ﬁndings emphasize
the importance of the presence of a circadian BDNF rhythm in
human health and well-being, while its absence seems to have a
negative impact on successful treatment outcome in MDD.
The decline in peripheral BDNF levels during the day may be
ascribed to a circadian secretory model on the one hand. Therefore,
it can be speculated that BDNF is secreted with a pulsatory circa-
dian rhythm that is characterized by a progressive reduction in the
amplitude of pulses throughout the day. On the other hand, it has
been shown that brain BDNF is able to cross the bloodebrain bar-
rier via a rapidly saturable transport system (Pan et al., 1998). While
brain BDNF peaks around midnight and thus may exert its modu-
lating effect on neuroplasticity and long-term potentiation (Liang
et al., 1998), peripheral BDNF in the blood, namely both, of
plasma and serum, peaks in the morning at 8 am and exhibits its
lowest expression level at midnight, indicating that BDNF cycles in
opposite phases in brain and blood. Why there is a discrepancy in
temporal expression proﬁles between blood and brain is not clear,
but might be due to a rapid transition from brain to blood with a
time delay of about 12 h or might reﬂect the endogenous circadian
rhythm of BDNF in the periphery which oscillates in anti-phase to
that of the brain. Importantly, this repeatedly reproduced result is
in line with ﬁndings of Sartorius and colleagues, who investigated
correlations and differences between serum and brain tissue BDNF
levels after ECT in rats (Sartorius et al., 2009). They demonstrated a
positive correlation between brain and serum BDNF concentrations
providing evidence that it can be justiﬁed to measure serum BDNF
levels but only by consideration of a time delay to monitor brain
tissue alterations in the periphery.
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BDNF are related to a circadian secretory model, sex hormones,
malfunctions in hypothalamicepituitaryeadrenal (HPA) axis
regulation, different activity during the day or other environmental
factors.
Moreover, the present study demonstrated that diurnal BDNF
serum variations were not changed by the adjuvant medication
with modaﬁnil as a stimulant during PSD, which is consistent with
our previous ﬁnding showing that modaﬁnil was not able to
enhance the antidepressive effects of PSD and did not stabilize
antidepressive effects over two weeks in these patients (Beck et al.,
2010). In addition, PSD itself had also no signiﬁcant impact on the
diurnal serum BDNF proﬁle. This further emphasizes the impor-
tance of the presence of a daily, circadian BDNF proﬁle at baseline
with regard to therapy response prediction. This is in line with data
from Wolkowitz et al. (2011) who also found that serum BDNF
levels (only measured at a single time point 10 am) before treat-
ment with SSRI (escitalopram or sertraline) predicted SSRI
response in depressed patients and that responders to treatment
exhibited higher pre-treatment BDNF levels than did non-
responders. Thus, one can speculate that diurnal BDNF variation
represents a prerequisite for successful therapy response inde-
pendent from the speciﬁc treatment strategy, e.g. antidepressants
drugs or SD.
Furthermore, our ﬁndings conﬁrmed that post-PSD BDNF serum
levels were higher in long-term (HDRS-6 ratings after two weeks)
responders (30% improvement in depression ratings) when
compared to non-responders. Increased BDNF serum levels (peak
levels at 8 am at day 1) were consistently associated with an
improvement of depressive symptoms in all patients. This was also
the case for pre-PSD serum BDNF levels (peak levels at 8 am at day
0). Our data are in line with other studies providing evidence that
an antidepressant-induced increase in BDNF levels is more prom-
inent in responders than non-responders (Okamoto et al., 2008) or
even exclusively restricted to responders (Lee and Kim, 2008),
while the early non-increase in serum BDNF levels predicted failure
of antidepressant treatment (different classes of antidepressants)
in patients with major depression (Tadic et al., 2011).
In the present study, post-PSD BDNF levels were investigated at
a very early stage of intervention, in this casewithin hours after PSD
(up to 18 h by using a 6 h interval post-PSD, speciﬁcally at 8 am, 2
pm, and 8 pm). This is in contrast to all other published studies
where treatment related BDNF changes were collected and
analyzed no earlier than one up to six weeks after antidepressive
therapy implicating classic antidepressants. Likewise with our re-
sults, recent studies applying the glutamate modulating compound
ketamine to treat depression, have demonstrated a rapid onset of
antidepressant effects (Berman et al., 2000; Liu et al., 2013; Zarate
et al., 2006). Haile and colleagues showed that plasma BDNF levels
increased 240 min post-infusion (0.5 mg/kg) in responders
compared to non-responders. Furthermore, signiﬁcantly increased
BDNF levels were negatively correlated with depression ratings and
highly predictive for clinical outcome up to 72 h post-infusion
(Haile et al., 2014). These ﬁndings support our data that early
changes of peripheral BDNF levels are already associated with
clinical outcome. Importantly, early changes of BDNF levels after
PSD and post-infusion of ketamine (Haile et al., 2014) underpin the
hypothesis of a rapid adaptation mechanism. Remodelling of syn-
apses and induction of neurogenesis (Duman and Aghajanian,
2014) attended by increased BDNF expression facilitates the hy-
pothesis of a peripheral secretory model, which would ﬁt with the
observation of a circadian pattern. It seems that rapid changes to
remodel neuronal networks involve the release of BDNF as a critical
backbone which might also occur in the periphery, since serum
BDNF levels increase within hours. However, we cannot concludewhether these peripheral changes of BDNF might stem from the
brain or peripheral sources, as in this study only serum was
assessed.
With good cause, the rapid effect of PSD reﬂected via BDNF
levels, might be related to the rapid antidepressant effect of PSD at
day 1, however relapse into depression occurs in most patients
following the recovery night (already at day 2) (Beck et al., 2010). In
agreement with our ﬁndings, others have consistently shown that
prolonged wakefulness as a result of sleep deprivation, which can
be considered as a stressor for the brain, leads to an increase in
BDNF (Conti et al., 2007), while sleep disturbance was linked to
reduction of BDNF levels (Giese et al., 2014), conﬁrming a bidirec-
tional stress model with which both can be explained. Chronic
stress induces a deregulation of the HPA system leading in the long-
term to sleep disturbances and decreased BDNF levels, whereas
acute sleep deprivation, e.g. PSD, can be used as therapeutic
intervention in some insomniac or depressed patients as a
compensatory process to normalize BDNF levels (Giese et al., 2013).
Thus, the present study adds very important new evidence to
the currently existing BDNF literature dealing with MDD: i) An a-
priori diurnal BDNF serum level variation precedes a more
favourable treatment outcome in depressive patients, and ii) PSD
may exert a very rapid effect on serum BDNF levels within a time
frame of several hours the day after PSD which parallels clinical
ﬁndings. This supports the release hypothesis regarding rapid BDNF
changes next to induced gene expression (Duman and Aghajanian,
2014). However, further results must be obtained in a larger patient
population where serum and plasma levels could reveal, if rapid
BDNF changes are related to induced gene expression and/or a
matter of rapid adaption reﬂected by a peripheral release in line
with a circadian proﬁle. While rapid increase in serum BDNF levels
after PSD suggests a direct effect of sleep deprivation; however, the
observed associations with treatment response at day 14 during
follow-up could be inﬂuenced also by long-term effects of the
mirtazapine treatment starting at baseline, which is a limitation of
our study.
For future studies, we suggest that next to analyses of pre- and
post-treatment serum BDNF levels collected at a single time point
per day, diurnal proof of peripheral BDNF should be monitored at
baseline especially before intervention starts for the purpose of
therapy response prediction. Moreover, the results of our study
might provide a valuable model for the investigation of biomarkers
in the treatment of MDD and other psychiatric disorders and might
encourage research in the area of early predictors of therapy
response in order to shorten the duration of psychopharmacolog-
ical treatment until the determination of insufﬁcient effectiveness.
Further studies with a larger number of patients and different
treatment strategies should be conducted to verify the results of
our exploratory investigation and to elucidate the underlying
mechanismsmore closely, especially the role of the stress hormone
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